The short‐term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct‐acting antivirals: An ERCHIVES study
Darrick K. Li, Yanjie Ren, Daniel S. Fierer, Stephanie Rutledge, Obaid S. Shaikh, Vincent Lo Re, Tracey Simon, Abdul‐Badi Abou‐Samra, Raymond T. Chung, Adeel A. Butt – 2 December 2017 – Recent studies have reported higher rates of hepatocellular carcinoma (HCC) in individuals treated with direct‐acting antivirals (DAAs). However, making definitive conclusions has been challenging because of the heterogeneous populations and methodologies of these reports.